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M TB currently infects ~2 billion people, one-third of the
world's population. Eight million new active cases occur
worldwide annually, more than at any previous time in
history. In addition, 14 million people are believed to be
co-infected with TB and HIV. In Africa, rising rates of TB
are clearly related to and a consequence of the devastating
co-existing HIV/AIDS epidemic. In the countries of the
former Soviet Union, and in many of the most populous
countries of Asia, already high TB infection and disease
rates may be further exacerbated as the full force of emerg-
ing HIV/AIDS epidemics are experienced. In this context,
resistance to drugs used to treat M TB has emerged as an
increasingly serious global public health emergency.
WHO surveillance over the past decade has shown grow-
ing rates of TB drug resistance, including multi-drug resist-
ant (MDR-TB), defined as resistance to isoniazid and
rifampin and newly defined extensively drug resistant
(XDR-TB), defined as MDR plus resistance to fluoroqui-
nolones, and at least one second-line injectable drug.
WHO estimated ~500,000 and 40,000 worldwide inci-
dent cases of MDR and XDR TB in 2006, respectively. The
recent report of XDR-TB in HIV co-infected patients in
South Africa has dramatically accelerated global aware-
ness of drug-resistant TB. Resistance may result either
from episodes of TB treatment failure or transmission of
resistant organisms. In either case, diagnosis is problem-
atic, treatment options markedly limited and high rates of
treatment failure and mortality occur, each further exag-
gerated by HIV co-infection. In sub-Saharan Africa, the
combination of a huge population of HIV-infected sus-
ceptible hosts, poor TB treatment success rates, lack of air-
borne infection control, limited drug-resistance testing,
and an overburdened TB and MDR TB treatment pro-
grams, has provided ideal conditions for an MDR and
XDR TB epidemic of unparalleled magnitude. M and XDR
TB pose great threats to individual patients and challenges
to the success of TB control programs and HIV/AIDS treat-
ment programs. This presentation will review drug-resist-
ant tuberculosis globally, with particular reference to
South Africa, describe its interaction with the HIV epi-
demic and resultant consequences, and suggest measures
necessary for controlling MDR and XDR TB in this con-
text. A successful clinical and public health response
necessitates infusion of new resources, earlier case find-
ing, attention to airborne infection control, new TB diag-
nostics and therapeutics and development of new
strategies, including increased collaboration between TB
and HIV programs.
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